Logo do repositório

Percorrer por autor "Matos, Leonor"

A mostrar 1 - 2 de 2
  • Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy
    Publication . Shai, Ayelet; Wildiers, Hans; Venieri, Claudio; Pogoda, Katarzyna; Linderholm, Barbro; Lambertini, Matteo; Matos, Leonor; D'Esposito, Eleonora De Maio; Hajjaji, Nawale; Matos, Erika; Cortijo, Lucía González; Fotia, Giuseppe; Fortuna, Ana; Sella, Tal; Gouveia, Helena; Rosset, Laurent; Constantinidou, Anastasia; Angeli, Eurydice; Cicin, Irfan; Tjan-Heijnen, Vivianne; Ruyssers, Natacha; Demasure, Sofie; Remilah, Areen Abu; Huygh, Greet; Shimon, Shani Paluch; Chiappe, Edoardo; Shirron, Natali; Neven, Patrick; Artac, Mehmet; Kilictas, Bilgesah; Baranseh, Jalal; Rubio, Elena Vicente; Atci, Mustafa; Amato, Ottavia; van Duijnhoven, Frederieke
    Background: The benefit of adjuvant ovarian function suppression (OFS) and aromatase inhibitors (AI) in premenopausal patients with hormone receptor positive, HER2 positive (HR+/HER2+) breast cancer (BC) is unclear. We aimed to investigate this question in a retrospective cohort, stratified by timing (adjuvant or neoadjuvant) of chemotherapy and trastuzumab and by response to neoadjuvant therapy. Methods: Patients aged <45Y at diagnosis, with stage I-III HR + HER2+ BC, treated with (neo)adjuvant chemotherapy and trastuzumab ( +/- pertuzumab) and endocrine therapy were included. LHRH-agonists and oophorectomy were considered OFS. We compared distant disease-free survival (DDFS) with tamoxifen, OFS + tamoxifen and OFS + AI in three cohorts: neoadjuvant-pathologic complete response (pCR), neoadjuvantresidual disease (RD) and adjuvant. Endocrine therapy (ET) was modeled as a time dependent covariate in cox logistic regression analyses. Results: The study included 1124 patients with median follow-up of 72.6 months (range:0-205 months). DDFS rates at 5 years were 83.9 %, 86.8 % and 92.1 % with tamoxifen, OFS + tamoxifen and OFS + AI respectively in the RD group, 94.3 %, 97.6 % and 96.5 % in the pCR group, and 94.3 %, 93.4 % and 98.6 % in the adjuvant group. OFS + AI was associated with better DDFS compared to tamoxifen in the RD group (n = 366) (multi-variable weighted HR 0.28. 95 % CI 0.11-.069, p = 0.006), but associations of ET with DDFS in the pCR (n = 307, p = 0.59) and adjuvant (n = 451, p = 0.18) cohorts were not detected. Stage III was associated with worse DDFS in all groups. Conclusion: OFS + AI were associated with better DDFS in patients with RD after neoadjuvant therapy. Our findings can assist shared decision-making on adjuvant endocrine therapy of these patients.
    2026-02Artigo científico Acesso aberto Ver mais
  • Flavobacterium magnesitis sp. nov. and Flavobacterium zubiriense sp. nov. two novel Flavobacterium species isolated from alkaline magnesite residues
    Publication . Matos, Leonor; Maccarrio, Lorrie; Chung, Ana Paula; Proença, Diogo Neves; Sørensen, Søren; Morais, Paula V; Francisco, Romeu
    Three bacterial strains, designated FZUC8N2.13, FBOR7N2.3 and FZUR7N2.5, were isolated from distinct magnesite residues in Spain. Phylogenetic and phylogenomic analysis places them within the genus . Strains FBOR7N2.3 and FZUR7N2.5 share 100% of similarity in the 16S rRNA gene sequence, and both are most closely related to AR-3-4 with which they share 97.5% of 16S rRNA gene similarity. Strain FZUC8N2.13 forms a distinct lineage most closely related to IMCC36792 with 97.7% 16S rRNA gene similarity. The closest phylogenomic neighbours of these three strains are DSM 1076, '' BBQ-18 and PK15. The average nucleotide identity and digital DNA-DNA hybridization values between the three strains and closest members of the genus are below the threshold values of 95% and 70%, respectively. Strains FZUC8N2.13, FBOR7N2.3 and FZUR7N2.5 stain Gram-negative, are rod-shaped and form yellow colonies. Optimum growth occurs at 25 °C and pH 7. The genomic G+C contents are 33.4 mol% for strain FZUC8N2.13 and 33.2 mol% for strains FBOR7N2.3 and FZUR7N2.5. The major isoprenoid quinone is menaquinone 6. The major fatty acids are summed feature 3 (C ω7c and/or C ω6c) (22.6-31.1%), iso-C (13.6-16.2 %) and anteiso-C (8.7-10.5%). The polar lipids consist of two aminolipids, two aminophospholipids and one glycolipid. The phylogenetic, phylogenomic, phenotypic and chemotaxonomic data indicate that FZUC8N2.13, FBOR7N2.3 and FZUR7N2.5 are distinct from the described species of and should be classified as novel species, for which we propose the names for strain FZUC8N2.13 (=UCCCB 179=CECT 30977) and for strains FBOR7N2.3 (=UCCCB 178=CECT 30976) and FZUR7N2.5 (=UCCCB 216=CECT 31036).
    2025-01Artigo científico Acesso restrito Ver mais